Released date: August 3, 2017

IL23 Inhibitors to the Rescue of Psoriatic Patients

The promise of selective IL-23 inhibitors in treating inflammatory diseases such as Psoriasis was borne out in mid-July 2017, when Janssen’s Tremfya® (guselkumab), a selective IL-23 inhibitor, was approved for the treatment of moderate to severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy. Janssen’s decision to use a priority review voucher for submission of the biologics license application was fruitful and led to guselkumab’s approval four months before its estimated PDUFA date of November 2017.